T. Mitsudomi

Cancer Research · 2004–2022

A researcher in the Science corpus: 14 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom T. Mitsudomi trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. T. Kosaka
2. William Pao
3. Fortunato Ciardiello

Papers from T. Mitsudomi's perspective

Ordered by how strongly the researchers T. Mitsudomi trusts endorse each paper. Same corpus, a different order for every researcher.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
4. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
5. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
6. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
7. Pathology and genetics of tumours of the lung , pleura, thymus and heart
8. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Proceedings of the National Academy of Sciences of the United States of America)
9. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. (Molecules and Cells)
10. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. (Genes & Development)

Their papers

• Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival (2004) — 2,552 citations
• Reduced expression of Dicer associated with poor prognosis in lung cancer patients (2005) — 652 citations
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007) — 4,374 citations
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008) — 647 citations
• Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (2022) — 2,035 citations
• Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. (2022) — 1,111 citations
• Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. (2017) — 816 citations
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) — 4,028 citations
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. (2010) — 1,200 citations
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) — 4,044 citations
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer (2007) — 615 citations
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib (2006) — 605 citations
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. (2005) — 960 citations
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer (2004) — 1,264 citations